Quarterly Activities/Appendix 4C Cash Flow Report
Released
Released
Announcement PDF
ASX Announcement – 28 October 2024
QUARTERLY ACTIVITIES & CASHFLOW REPORT
Highlights
•
•
•
•
•
•
•
Receipts from customers of $3.2M - up 186% or $2.07M from pcp FY23 of $1.12M, and
down 16% or $0.59M from the June quarter of $3.77M
Record cash receipts from customers over 12 months to 30 Sep 2024 of $10.2M up
133% or $5.8M from pcp to 30 Sep 2023
Cashflows from operating activities of -$0.1M, and net positive cashflows from
operating activities of $1.96M for the 12 months to 30 Sep 2024
Major clinical trial announced in Aug 2023 progressing to schedule with patient
recruitment completed in August 2024
Deferred acquisition payments and investment in new TrialsWest site made during the
quarter, total cashflows used in investment activities of $0.8M
TrialsWest trading ahead of initial expectations with new trial site operational
Cash at bank of $5.78M at the end of the quarter
Resonance Health Ltd (ASX: RHT) (Resonance Health or Company) is pleased to release its Appendix 4C and
Quarterly Activities & Cashflow Report for the quarter ended 30 September 2024.
Major Milestones
The Company continues to rapidly and profitably scale up its operations with the continued execution of its
strategy to drive growth in its 3 businesses, Software-as-a-Medical Device (SaMD), Clinical Trial Management
(CRO Services), and Clinical Trial Site Services (TrialsWest).
Strong trading in TrialsWest has resulted in first quarter performance above expectations. The addition of a
second trial site north of Perth, Western Australia, is expected to contribute to revenue in the December
2024 quarter. TrialsWest continues to grow through its ability to recruit strong participation of patients into
clinical trials due to increased capacity and a move into clinical trials in additional therapeutic areas.
TrialsWest’s low-cost community-based approach to site expansion is expected to continue with new sites
planned in future periods that will drive organic revenue and earnings growth. Notably, capital expenditure
associated with the establishment of the 2nd TrialsWest Site was only circa $80K.
The Company’s CRO Services business, which is serving as CRO and local Australian sponsor for a major global
pharma company’s Clinical Trial (see ASX release dated 18 Aug 2023), is continuing to progress the clinical
trial with patient recruitment completed in August 2024. There remains ~$1.8M to be invoiced until the
completion of this trial which is expected to occur in the current financial year.
Resonance Health Ltd ABN: 96 006 762 492
141 Burswood Road, Burswood, WA 6100, AUSTRALIA
Postal: PO Box 108, Victoria Park, WA 6979, AUSTRALIA
www.resonancehealth.com
T + 61 8 9286 5300
info@resonancehealth.com
The Company’s global SaMD business continued to grow with analysis volumes trending upwards during the
quarter along with several new customer sites being setup globally to use Resonance Health’s SaMD
products.
Development of the Company’s new Non-Invasive MRI Liver Fibrosis SaMD product is progressing well
through its Extended-Proof-of-Concept Trial (EPOC).
Significant progress was made on internal SaMD development projects that are expected to deliver
substantial increases in the Company’s report generation capacity and capability. Once embedded into the
Company’s service centre, these improvements will allow for expected future demand associated with new
products and services such as the Non-Invasive MRI Liver Fibrosis SaMD product. These projects involve
process automation utilising new artificial intelligence and have to date produced impressive results in
testing.
Financial & Operating Performance
Continued strong demand in diagnostics, clinical trials, and milestone payments earned in the Company’s
CRO Services business contributed to receipts of $3.2M for the quarter, an increase of 186% compared to
the FY23 pcp of $1.12M.
Total receipts for the 12 months to 30 Sep 2024 were $10.2M up 133% compared to full year pcp receipts of
$4.38M.
The Company’s balance sheet remains strong with a cash balance of $5.78M at the end of quarter. The
Company has a $3.2M senior debt facility with NAB that was established to partially finance the TrialsWest
acquisition. On 30 Sep 2024 there was $3.09M outstanding under the NAB facility.
With respect to item 6 of the Appendix 4C cash flow report for the quarter, payments to related parties of
approximately $99K were made during the quarter. This comprised of $37.5K paid to Mr Mitchell Wells for
consulting and company secretarial services provided during the quarter. The balance was remuneration
paid to non-executive directors for their services.
This announcement has been authorised for release in accordance with the delegated authority of the Board
of Directors of Resonance Health Ltd. For further information please contact:
Andrew Harrison – Chief Executive Officer
E: andrewh@resonancehealth.com
P: +61 (0)8 9286 5300
About Resonance Health
Resonance Health is an Australian healthcare technology and services company. The Company’s services are
used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic
companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide
for providing high quality quantitative assessments essential in managing diseases and drug development.
Resonance Health’s dedication to scientific rigour and quality has enabled it to achieve regulatory clearances
for a range of Software-as-Medical Devices (SaMDs) in the USA, Europe, UK, and Australia, and to proudly
carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD
products, some of which incorporate Artificial Intelligence (AI), include:
Page 2
§ FerriScan®, a core-lab product that provides an accurate assessment of liver iron concentration (LIC)
through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload
conditions. Internationally recognised as the gold standard in LIC assessment.
§ FerriSmart®, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC
in patients, calibrated against the global gold standard, FerriScan®.
§ HepaFatScan®, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in
liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
§ HepaFatSmart ®, an AI-trained, non-invasive device for the automated real-time multi-metric assessment
of liver-fat in patients, for the assessment of individuals with confirmed or suspected fatty liver disease.
§ LiverSmart®, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and
HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat.
§ CardiacT2*, the most widely accepted MRI method for assessing heart iron loading. Resonance Health
offers a dual analysis of FerriScan® and CardiacT2*. CardiacT2* is TGA and CE Marking regulatory cleared.
The Company has a development pipeline of additional medical imaging analysis products and services,
including the MRI Liver Fibrosis Project, aimed at accurately assessing the presence and progression of liver
fibrosis utilising non-invasive MRI analysis.
The Company also operates Clinical Trial Management (CRO Services) and Clinical Trial Site (TrialsWest)
businesses that cater to global clinical trial customers.
Stakeholders, including clinicians, patients, and shareholders, are encouraged to register their interest at
www.resonancehealth.com and to follow Resonance Health on LinkedIn.
Page 3
Rule 4.7B
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
Resonance Health Limited
ABN
Quarter ended (“current quarter”)
96 006 762 492
30 September 2024
Consolidated statement of cash flows
Current quarter
$A’000
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
Year to date (3
months)
$A’000
3,186
3,186
(254)
(254)
(192)
(192)
(e) staff costs
(1,207)
(1,207)
(f)
(1,675)
(1,675)
28
28
26
26
(88)
(88)
(b) businesses
(698)
(698)
(c) property, plant and equipment
(92)
(92)
(42)
(42)
(a) research and development
(b) product manufacturing and operating
costs
(c) advertising and marketing
(d) leased assets
administration and corporate costs
1.3
Dividends received (see note 3)
1.4
Interest received
1.5
Interest and other costs of finance paid
1.6
Income taxes paid
1.7
Government grants and tax incentives
1.8
Other (provide details if material)
1.9
Net cash from / (used in) operating
activities
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
(a) entities
(d) investments
(e) intellectual property
(f)
other non-current assets
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 1
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
2.2
Current quarter
$A’000
Year to date (3
months)
$A’000
Proceeds from disposal of:
(a) entities
(b) businesses
(c) property, plant and equipment
(d) investments
(e) intellectual property
(f)
other non-current assets
2.3
Cash flows from loans to other entities
2.4
Dividends received (see note 3)
2.5
Other (provide details if material)
2.6
Net cash from / (used in) investing
activities
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
3.2
Proceeds from issue of convertible debt
securities
3.3
Proceeds from exercise of options
3.4
Transaction costs related to issues of
equity securities or convertible debt
securities
3.5
Proceeds from borrowings
3.6
Repayment of borrowings
3.7
Transaction costs related to loans and
borrowings
3.8
Dividends paid
3.9
Other:
(832)
(832)
(80)
(80)
- Lease payments
(59)
(59)
- Net payments for cash backed
guarantees
(12)
(12)
3.10
Net cash from / (used in) financing
activities
(151)
(151)
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
6,854
6,854
(88)
(88)
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 2
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
Current quarter
$A’000
Year to date (3
months)
$A’000
4.3
Net cash from / (used in) investing activities
(item 2.6 above)
(832)
(832)
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
(151)
(151)
4.5
Effect of movement in exchange rates on
cash held
(7)
(7)
4.6
Cash and cash equivalents at end of
period
5,776
5,776
5.
Reconciliation of cash and cash
equivalents
Current quarter
$A’000
Previous quarter
$A’000
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
5.1
Bank balances
5,760
3,403
5.2
Call deposits
16
3,450
5.3
Bank overdrafts
5.4
Other (provide details)
5.5
Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
5,776
6,854
6.
Payments to related parties of the entity and their
associates
6.1
Aggregate amount of payments to related parties and their
associates included in item 1
6.2
Aggregate amount of payments to related parties and their
associates included in item 2
Current quarter
$A'000
99
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an
explanation for, such payments.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 3
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
7.
Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
$A’000
Amount drawn at
quarter end
$A’000
3,093
3,093
3,093
3,093
7.1
Loan facilities
7.2
Credit standby arrangements
7.3
Other (please specify)
7.4
Total financing facilities
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
NIL
Secured Financing Facility from National Australia Bank, facility expiry date is 31 March
2027. Interest rate is BBSY + 2.5% per annum.
8.
Estimated cash available for future operating activities
$A’000
8.1
Net cash from / (used in) operating activities (item 1.9)
(88)
8.2
Cash and cash equivalents at quarter end (item 4.6)
5,776
8.3
Unused finance facilities available at quarter end (item 7.5)
8.4
Total available funding (item 8.2 + item 8.3)
5,688
8.5
Estimated quarters of funding available (item 8.4 divided by
item 8.1)
65.61
-
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer: N/A
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer: N/A
8.6.3
Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer: N/A
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 4
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
Date:
28 October 2024
Authorised by: By the Board of Directors of Resonance Health Limited
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4.
If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5.
If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 5
Share your feedback
Discover